Keywords: eloxatin, cleared, fda, 1st, line, therapy, french
Eloxatin cleared by FDA as 1st line therapy
Article | 19 January 2004
French drug major Sanofi-Synthelabo's Eloxatin (oxaliplatin for injection) in combination with 5-fluorouracil/leucovorin has been approved by the US Food ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
